SEC Form 4 · accession 0001225208-16-028387
PFIZER INC · PFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John D Young
Officer — Group President
Period of report
Feb 24, 2016
Accepted (ET)
Feb 26, 2016 · 3:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000078003
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 24, 2016 | M | 52,570 | $18.90 | A | 188,679 | D | |
| Common StockF2 | Feb 24, 2016 | F | 11,854 | $30.02 | D | 176,825 | D | |
| Common StockF3,F4 | Feb 24, 2016 | F | 24,806 | $29.67 | D | 152,019 | D | |
| Common Stock | holding | — | — | — | 1,159 | I | By Rule 16b-3 Plan | |
| Common Stock | holding | — | — | — | 1,339 | I | By Trustee under the Pfizer Share Ownership Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation RightsF5 | $18.90 | Feb 24, 2016 | M | 52,570 | D | Feb 24, 2016 | Feb 24, 2016 | Common Stock | 52,570 | 0 | D |
| Stock Appreciation RightsF5 | $30.59 | Feb 25, 2016 | A | 155,172 | A | Feb 25, 2021 | Feb 25, 2021 | Common Stock | 155,172 | 155,172 | D |
| Stock Appreciation RightsF6 | $30.59 | Feb 25, 2016 | A | 138,675 | A | Feb 25, 2023 | Feb 25, 2023 | Common Stock | 138,675 | 138,675 | D |
Explanation of responses
- F1The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
- F2The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
- F3The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
- F4Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
- F5The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
- F6The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.